期刊文献+

靶向沉默p65基因对人三阴乳腺癌细胞增殖的影响 被引量:1

下载PDF
导出
摘要 目的利用siRNA靶向沉默p65基因,观察其对三阴乳腺癌细胞系MDA-MB-468、MDA-MB-453体外增殖的影响,从而证实p65对三阴乳腺癌细胞系影响的普遍性。方法以脂质体Lipofectamine TM3000为载体,将针对p65基因的特异性靶点转入人乳腺癌细胞MDA-MB-468、MDA-MB-453细胞;realtime-PCR法检测p65mRNA的表达变化;细胞计数法检测细胞增殖。结果 realtime-PCR检测结果显示,p65siRNA转染组相对于对照组p65mRNA表达显著下降(P<0.05);细胞增殖显示,沉默p65基因后,细胞出现生长抑制现象。结论 siRNA靶向沉默p65基因可抑制人乳腺癌细胞增殖,推测p65对三阴乳腺癌细胞系影响的具有普遍性。
出处 《临床合理用药杂志》 2016年第11期114-115,共2页 Chinese Journal of Clinical Rational Drug Use
基金 靶向沉默NF-κB p65基因表达对三阴乳腺癌细胞株MDA-MB-436细胞凋亡及周期的影响 (编号:吉教科合字【2014】第604号)
  • 相关文献

参考文献5

  • 1Finn R S,Crown J P,Lang I,et al.The cyclin-dependent kinase4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2-negative,advanced breast cancer(PALOMA-1/TRIO-18):a randomised phase 2 study[J].The Lancet Oncology,2015,16(1):25-35.
  • 2Giese-Davis J,Wilhelm F H,Tamagawa R,et al.Higher vagal activity as related to survival in patients with advanced breast cancer:An analysis of autonomic dysregulation[J].Psychosomatic medicine,2015,77(4):346-355.
  • 3王玲,单保恩,桑梅香,连易水,王彬,丁春艳.靶向沉默p65基因对人乳腺癌细胞MDA-MB-231增殖及凋亡的影响[J].南方医科大学学报,2011,31(10):1742-1747. 被引量:12
  • 4Kendellen M F,Bradford J W,Lawrence C L,et al.Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells[J].Oncogene,2014,33(10):1297-1305.
  • 5Rabi T,Huwiler A,Zangemeister-Wittke U.AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells[J].Molecular carcinogenesis,2014,53(7):578-588.

二级参考文献12

  • 1Autier P, Hery C, Haukka J, et al. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening [J]. J Clin Oncol, 2009, 27(35): 5919-23.
  • 2McCracken M, Olsen M, Chen MS Jr, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities [J].CA Cancer J Clin, 2007, 57(4): 190-205.
  • 3Biswas DK, Dai SC, Cruz A, et al. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers[ J]. Proc Natl Acad Sci U S A, 2001, 98(18): 10386-91.
  • 4Singh S, Shi Q, Bailey ST, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer [J]. Mol Cancer Ther, 2007, 6(7): 1973-82.
  • 5Basak S, Hoffmann A. Crosstalk via the NF-kappaB signaling system [J]. Cytokine Growth Factor Rev, 2008, 19(3-4): 187-97.
  • 6Wang QZ, Xu W, Habib N, et al. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy [J]. Curr Cancer Drug Targets, 2009, 9(4): 572-94.
  • 7Rao DD, Senzer N, Cleary MA, et al. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development [J]. Cancer Gene Ther, 2009, 16(11): 807-9.
  • 8Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis [J]. Methods Mol Biol, 2008, 414: 13-21.
  • 9Kuribayashi K, Mayes PA, El-Deiry WS. What are caspases 3 and 7 doing upstream of the mitochondria [J]. Cancer Biol Ther, 2006, 5 (7): 763-5.
  • 10Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment [J]. Br Med Bull, 2009, 89: 23-40.

共引文献11

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部